DIADIA0.56%
SPYSPY0.17%
QQQQQQ0.56%
Trending
Top trending tickerBBBB16.87%
MRVLMRVL41.28%
GMEGME5.71%
PANWPANW1.84%
BTCBTC4.84%
GTLBGTLB13.10%
SOXSSOXS18.53%
ULTAULTA0.55%
SOXXSOXX6.26%
ETHETH4.70%
Top trending tickerBBBB16.87%
MRVLMRVL41.28%
GMEGME5.71%
PANWPANW1.84%
BTCBTC4.84%
GTLBGTLB13.10%
SOXSSOXS18.53%
ULTAULTA0.55%
SOXXSOXX6.26%
ETHETH4.70%
PGEN logo

PGENPrecigen Inc

$3.88
$0.26
(6.31%)
Today
Closed $3.86
$0.02
(0.52%)
After Hours
Updated: 05:27 PM EDT
Reported EarningsMay 13
Mkt Cap$1.47B
Vol9.64M
54

Neutral Sentiment

How do you feel about PGEN?

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
News Placeholder
More News
News Placeholder
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete...
PR Newswire
News Placeholder
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States PR Newswire GERMANTOWN, Md., May 27, 2026 FDA grants orphan drug exclusivity for...
PR Newswire
News Placeholder
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire GERMANTOWN, Md., May 26, 2026...
PR Newswire
News Placeholder
Precigen’s Lead Cancer Therapy Is Fueling A Massive Stock Rally — Here’s What Wall Street Sees Next
Driven by Papzimeos sales, Precigen posted a revenue of $23.3 million, which came in above Wall Street’s estimates of $20.8 million, according to Fiscal.ai data.
Stocktwits
News Placeholder
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
Precigen (PGEN) delivered earnings and revenue surprises of +20.00% and +9.99%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen Reports First Quarter 2026 Financial Results and Business Updates Precigen Reports First Quarter 2026 Financial Results and Business Updates PR Newswire GERMANTOWN, Md., May 13, 2026...
PR Newswire
News Placeholder
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13 Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13 PR...
PR Newswire
News Placeholder
Precigen (PGEN) to Release Earnings on Wednesday
Precigen (NASDAQ:PGEN) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
News Placeholder
Precigen (NASDAQ:PGEN) Stock Crosses Below 200 Day Moving Average - Here's Why
Precigen (NASDAQ:PGEN) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell...
MarketBeat
<
1
2
...
>
Top Discussions

Advertisement|Remove ads.